推薦產品
等級
pharmaceutical primary standard
API 家族
acitretin
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C
InChI
1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
InChI 密鑰
IHUNBGSDBOWDMA-AQFIFDHZSA-N
基因資訊
human ... RARA(5914) , RARB(5915) , RARG(5916) , RXRA(6256) , RXRB(6257) , RXRG(6258)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Acitretin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Acitretin Capsules
生化／生理作用
合成维甲酸，是依曲甲酸酯的代谢物。 优先与细胞视黄酸结合蛋白（CRABP） 结合。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
F Aydin et al.
Clinical and experimental dermatology, 32(6), 683-686 (2007-08-24)
Keratoacanthoma centrifugum marginatum (KCM) is a rare entity, usually classified as solitary keratoacanthoma (KA). The Ferguson-Smith type is the most common form of multiple KAs. Because development of multiple KAs and KCM in a single patient has rarely been reported
Rashmi Sarkar et al.
Indian journal of dermatology, venereology and leprology, 79(6), 759-771 (2013-11-02)
Acitretin, a synthetic retinoid has gradually replaced etretinate in today's dermatologic practice because of its more favorable pharmacokinetics. Acitretin over the past 20 years has proven useful in a number of difficult-to-treat hyperkeratotic and inflammatory dermatoses and nonmelanoma skin cancers.
Christoffer Ingves et al.
Scandinavian journal of plastic and reconstructive surgery and hand surgery, 37(5), 293-295 (2003-12-03)
We report the successful outcome of treatment of a basal cell carcinoma (BCC) with topical imiquimod and systemic acitretin in a 48-year-old woman. We think that this treatment is a possible option for management of these non-life-threatening tumours. Experimental evidence
Lauren K Dunn et al.
Journal of drugs in dermatology : JDD, 10(7), 772-782 (2011-07-02)
Acitretin is a systemic retinoid drug used in the treatment of severe psoriasis. It has also been used for a spectrum of other difficult-to-treat dermatoses, including hyperkeratotic and inflammatory dermatoses and non-melanoma skin cancers. Here we review the available data
Taru Garg et al.
Dermatology online journal, 17(5), 3-3 (2011-06-04)
Linear porokeratosis is a rare disorder of keratinization that usually presents at birth. We report a 17-year-old male with generalized linear porokeratosis, a very rare variant of porokeratosis, with extensive involvement of the trunk and extremities along with nail and
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務